Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study

M A Frouws; E Bastiaannet; R E Langley; W K Chia; M P P van Herk-Sukel; V E P P Lemmens; H Putter; H H Hartgrink; B A Bonsing; C J H Van de Velde; J E A Portielje; G J Liefers

doi:10.1038/bjc.2016.425

Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study

M A Frouws, E Bastiaannet, R E Langley, W K Chia, M P P van Herk-Sukel, V E P P Lemmens, H Putter, H H Hartgrink, B A Bonsing, C J H Van de Velde, J E A Portielje, G J Liefers

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: Previous studies suggested a relationship between aspirin use and mortality reduction. The mechanism for the effect of aspirin on cancer outcomes remains unclear. The aim of this study was to evaluate aspirin use and survival in patients with gastrointestinal tract cancer.

METHODS: Patients with gastrointestinal tract cancer diagnosed between 1998 and 2011 were included. The population-based Eindhoven Cancer Registry was linked to drug-dispensing data from the PHARMO Database Network. The association between aspirin use after diagnosis and overall survival was analysed using Cox regression models.

RESULTS: In total, 13 715 patients were diagnosed with gastrointestinal cancer. A total of 1008 patients were identified as aspirin users, and 8278 patients were identified as nonusers. The adjusted hazard ratio for aspirin users vs nonusers was 0.52 (95% CI 0.44-0.63). A significant association between aspirin use and survival was observed for patients with oesophageal, hepatobiliary and colorectal cancer.

CONCLUSIONS: Post-diagnosis use of aspirin in patients with gastrointestinal tract malignancies is associated with increased survival in cancers with different sites of origin and biology. This adds weight to the hypothesis that the anti-cancer effects of aspirin are not tumour-site specific and may be modulated through the tumour micro-environment.

Original language	English
Pages (from-to)	405-413
Number of pages	9
Journal	British Journal of Cancer
Volume	116
Issue number	3
DOIs	https://doi.org/10.1038/bjc.2016.425
Publication status	Published - Jan 2017
Externally published	Yes

Keywords

Journal Article

Access to Document

10.1038/bjc.2016.425

Cite this

Frouws, M. A., Bastiaannet, E., Langley, R. E., Chia, W. K., van Herk-Sukel, M. P. P., Lemmens, V. E. P. P., Putter, H., Hartgrink, H. H., Bonsing, B. A., Van de Velde, C. J. H., Portielje, J. E. A., & Liefers, G. J. (2017). Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study. British Journal of Cancer, 116(3), 405-413. https://doi.org/10.1038/bjc.2016.425

@article{6c2baec1821c42d48daf31bd5c9a2ad7,

title = "Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study",

abstract = "BACKGROUND: Previous studies suggested a relationship between aspirin use and mortality reduction. The mechanism for the effect of aspirin on cancer outcomes remains unclear. The aim of this study was to evaluate aspirin use and survival in patients with gastrointestinal tract cancer.METHODS: Patients with gastrointestinal tract cancer diagnosed between 1998 and 2011 were included. The population-based Eindhoven Cancer Registry was linked to drug-dispensing data from the PHARMO Database Network. The association between aspirin use after diagnosis and overall survival was analysed using Cox regression models.RESULTS: In total, 13 715 patients were diagnosed with gastrointestinal cancer. A total of 1008 patients were identified as aspirin users, and 8278 patients were identified as nonusers. The adjusted hazard ratio for aspirin users vs nonusers was 0.52 (95% CI 0.44-0.63). A significant association between aspirin use and survival was observed for patients with oesophageal, hepatobiliary and colorectal cancer.CONCLUSIONS: Post-diagnosis use of aspirin in patients with gastrointestinal tract malignancies is associated with increased survival in cancers with different sites of origin and biology. This adds weight to the hypothesis that the anti-cancer effects of aspirin are not tumour-site specific and may be modulated through the tumour micro-environment.",

keywords = "Journal Article",

author = "Frouws, {M A} and E Bastiaannet and Langley, {R E} and Chia, {W K} and {van Herk-Sukel}, {M P P} and Lemmens, {V E P P} and H Putter and Hartgrink, {H H} and Bonsing, {B A} and {Van de Velde}, {C J H} and Portielje, {J E A} and Liefers, {G J}",

note = "Publisher Copyright: {\textcopyright} 2017 The Author(s).",

year = "2017",

month = jan,

doi = "10.1038/bjc.2016.425",

language = "English",

volume = "116",

pages = "405--413",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "3",

}

Frouws, MA, Bastiaannet, E, Langley, RE, Chia, WK, van Herk-Sukel, MPP, Lemmens, VEPP, Putter, H, Hartgrink, HH, Bonsing, BA, Van de Velde, CJH, Portielje, JEA & Liefers, GJ 2017, 'Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study', British Journal of Cancer, vol. 116, no. 3, pp. 405-413. https://doi.org/10.1038/bjc.2016.425

TY - JOUR

T1 - Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study

AU - Frouws, M A

AU - Bastiaannet, E

AU - Langley, R E

AU - Chia, W K

AU - van Herk-Sukel, M P P

AU - Lemmens, V E P P

AU - Putter, H

AU - Hartgrink, H H

AU - Bonsing, B A

AU - Van de Velde, C J H

AU - Portielje, J E A

AU - Liefers, G J

PY - 2017/1

Y1 - 2017/1

N2 - BACKGROUND: Previous studies suggested a relationship between aspirin use and mortality reduction. The mechanism for the effect of aspirin on cancer outcomes remains unclear. The aim of this study was to evaluate aspirin use and survival in patients with gastrointestinal tract cancer.METHODS: Patients with gastrointestinal tract cancer diagnosed between 1998 and 2011 were included. The population-based Eindhoven Cancer Registry was linked to drug-dispensing data from the PHARMO Database Network. The association between aspirin use after diagnosis and overall survival was analysed using Cox regression models.RESULTS: In total, 13 715 patients were diagnosed with gastrointestinal cancer. A total of 1008 patients were identified as aspirin users, and 8278 patients were identified as nonusers. The adjusted hazard ratio for aspirin users vs nonusers was 0.52 (95% CI 0.44-0.63). A significant association between aspirin use and survival was observed for patients with oesophageal, hepatobiliary and colorectal cancer.CONCLUSIONS: Post-diagnosis use of aspirin in patients with gastrointestinal tract malignancies is associated with increased survival in cancers with different sites of origin and biology. This adds weight to the hypothesis that the anti-cancer effects of aspirin are not tumour-site specific and may be modulated through the tumour micro-environment.

AB - BACKGROUND: Previous studies suggested a relationship between aspirin use and mortality reduction. The mechanism for the effect of aspirin on cancer outcomes remains unclear. The aim of this study was to evaluate aspirin use and survival in patients with gastrointestinal tract cancer.METHODS: Patients with gastrointestinal tract cancer diagnosed between 1998 and 2011 were included. The population-based Eindhoven Cancer Registry was linked to drug-dispensing data from the PHARMO Database Network. The association between aspirin use after diagnosis and overall survival was analysed using Cox regression models.RESULTS: In total, 13 715 patients were diagnosed with gastrointestinal cancer. A total of 1008 patients were identified as aspirin users, and 8278 patients were identified as nonusers. The adjusted hazard ratio for aspirin users vs nonusers was 0.52 (95% CI 0.44-0.63). A significant association between aspirin use and survival was observed for patients with oesophageal, hepatobiliary and colorectal cancer.CONCLUSIONS: Post-diagnosis use of aspirin in patients with gastrointestinal tract malignancies is associated with increased survival in cancers with different sites of origin and biology. This adds weight to the hypothesis that the anti-cancer effects of aspirin are not tumour-site specific and may be modulated through the tumour micro-environment.

KW - Journal Article

U2 - 10.1038/bjc.2016.425

DO - 10.1038/bjc.2016.425

M3 - Article

C2 - 28072768

SN - 0007-0920

VL - 116

SP - 405

EP - 413

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 3

ER -

Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study

Abstract

Keywords

Access to Document

Fingerprint

Cite this